Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17129602 | 0.92 | L3MBTL1 (0.57) | TDP1L3MBTL1NOTUMTSHRTTR | |
| SCHEMBL3065854 | 0.90 | HDAC6 (0.54) | TSHRMAPTKMT2AMEN1PTGER4 | |
| SCHEMBL9478194 | 0.88 | L3MBTL1 (0.56) | TDP1L3MBTL1NOTUMTSHRTTR | |
| SCHEMBL6507828 | 0.88 | TDP1 (0.52) | TDP1L3MBTL1TTRALDH1A1MAPT | |
| SCHEMBL13069056 | 0.87 | TSHR (0.47) | TSHRALDH1A1RENKMT2AMEN1 | |
| SCHEMBL2936694 | 0.86 | TSHR (0.53) | TDP1TSHRTTRALDH1A1CA12 | |
| SCHEMBL17991551 | 0.86 | TDP1 (0.54) | TDP1L3MBTL1NOTUMTSHRTTR | |
| SCHEMBL26048876 | 0.86 | ALDH1A1 (0.55) | TDP1L3MBTL1NOTUMTSHRTTR | |
| SCHEMBL22160224 | 0.85 | ALDH1A1 (0.51) | TDP1L3MBTL1TSHRTTRALDH1A1 | |
| SCHEMBL17991550 | 0.85 | NOTUM (0.59) | TDP1L3MBTL1NOTUMTSHRTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| WO-2009053277-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053277-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008107365-A1 | NEW COMPOUNDS | MEDIVIR AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107365-A1 | NEW COMPOUNDS | MEDIVIR AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1863477-A1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | Novartis AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006100036-A1 | 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | TDP1 2032/4885L3MBTL1 4239/4885NOTUM 1000/4885 |
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | TDP1 1106/4885L3MBTL1 4426/4885NOTUM 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.